Investor's Business Daily on MSN
Why IBD stock of the day Harrow has its sights on a breakout
Harrow is Monday's IBD Stock Of The Day. The biotech stock is setting up to tack a handle onto a seven-week cup.
Zacks Investment Research on MSN
Harrow (HROW) reports next week: Wall Street expects earnings growth
The market expects Harrow (HROW) to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...
In late September 2025, Harrow, Inc. launched the Harrow Access for All (HAFA) program, expanding affordable and predictable pricing for its full portfolio of branded, generic, and compounded ...
NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its ...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026 ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic ...
Harrow has the U.S. commercial rights to 10 branded ophthalmic pharmaceutical products approved by the Food and Drug Administration (FDA). Harrow also owns ImprimisRx, a leading U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results